MyChesCo on MSN

Johnson & Johnson’s Oral Psoriasis Drug Shows Strong Long-Term Results

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced new one-year data showing that its investigational oral drug ...

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...
Managed Healthcare Executive

Icotrokinra Demonstrates High Clearance Rates in Plaque Psoriasis | Fall Clinical Derm 2025

New long-term data of the investigational therapy icotrokinra show that it is able to achieve site-specific clear or almost clear skin in patients with plaque psoriasis, according to results of the ...

Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and ...

Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-TOTAL studya evaluating icotrokinra, a first-in-class investigational targeted oral peptide that ...

Psoriasis Isn't Just Skin Deep, It Impacts Mental Health Too: Survivor Explains

Psoriasis isn't just a skin condition. It's an autoimmune disease that can shape your mental and emotional world too.

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628, for the Phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers (DFU) patients ...